AAMP

AAMP is a WD40- and immunoglobulin-domain-containing protein, distributed both intracellularly and at the cell surface, that governs cell migration, angiogenesis, and innate immune signaling primarily by acting as a positive regulator of Rho-family GTPases and the actin cytoskeleton (PMID:8683944, PMID:26350504, PMID:39404373). Its amino-terminal positively charged region binds heparin with high affinity and mediates heparin-sensitive, glycosaminoglycan-dependent cell binding and clustering, and anti-AAMP antibody blocks endothelial tube formation (PMID:8683944, PMID:18634104). In vascular endothelial cells AAMP is recruited by VEGF to membrane protrusions and is required for VEGF-induced tube formation, aortic ring sprouting, actin stress fiber formation, and gel contraction through RhoA/Rho-kinase signaling (PMID:26350504). Mechanistically, AAMP binds RhoA directly and protects it from SMURF2-mediated ubiquitination and degradation, thereby raising active RhoA levels (PMID:34901393), regulates the stability and activity of both RhoA and RhoB and colocalizes with F-actin and cortactin at membrane ruffles where it constrains endothelial barrier function (PMID:39404373), and binds CDC42 to promote its activation by impeding the ARHGAP1–CDC42 interaction (PMID:33279622); collectively these activities drive cancer cell adhesion, growth, and invasion (PMID:23564791, PMID:33279622, PMID:34901393). Independently of its cytoskeletal role, AAMP interacts via its WD40 domains with the NLR protein Nod2 and modulates Nod1/Nod2-driven NF-κB activation (PMID:19535145), and binds the co-stimulatory protein B7-H3 to influence T-cell proliferation (PMID:35919070).

1. 1996 Medium

   Established AAMP as a multidomain protein with both intracellular and extracellular distribution and a functional role in angiogenesis, defining the structural features that frame all later mechanistic work.

   Evidence Sequence analysis, heparin binding assay, anti-AAMP antibody inhibition of endothelial tube formation, and immunofluorescence in endothelial cells

   PMID:8683944

   Open questions at the time

   • No direct demonstration of the molecular partners through which AAMP acts on tube formation
   • Functional role of the transmembrane region and acidic domain untested
2. 1996 Medium

   Characterized a shared ESESES epitope between AAMP and alpha-actinin and showed it is presented differently, distinguishing AAMP structurally from a cytoskeletal protein it superficially resembles.

   Evidence Peptide competition, thermolysin limited proteolysis, and immunoperoxidase staining

   PMID:8660919

   Open questions at the time

   • Epitope sharing does not establish a functional or interaction relationship with alpha-actinin
3. 1997 Medium

   Mapped AAMP's heparin-binding and cell-clustering activity to its amino-terminal P189 peptide and linked it to cell-surface glycosaminoglycans, providing a basis for its extracellular adhesive function.

   Evidence Saturable heparin binding assay, GAG-dependent cell binding/clustering with inhibitors, peptide variant substitutions, and electron microscopy; tumor cell migration partially inhibited by peptide

   PMID:18634104

   Open questions at the time

   • Activity demonstrated with aggregated synthetic peptide rather than full-length native protein
   • Physiological GAG receptor not identified
4. 2009 High

   Connected AAMP to innate immunity by identifying it as a Nod2 interactor that tunes NF-κB activation, expanding AAMP's role beyond migration into NLR signaling.

   Evidence Yeast two-hybrid, reciprocal co-immunoprecipitation, WD40-domain mapping, siRNA/overexpression, and NF-κB reporter assays in HEK293T

   PMID:19535145

   Open questions at the time

   • Position of AAMP within the Nod2 signaling complex not resolved
   • No in vivo confirmation of effect on inflammatory responses
5. 2013 Medium

   Demonstrated that AAMP is functionally required for breast cancer cell adhesion, growth, and invasion, establishing a pro-tumorigenic loss-of-function phenotype.

   Evidence Hammerhead ribozyme knockdown with adhesion, growth, and invasion assays in MCF-7 and MDA-MB-231 cells

   PMID:23564791

   Open questions at the time

   • No molecular pathway linked to the phenotypes in this study
   • No in vivo tumor model
6. 2015 Medium

   Placed AAMP within VEGF-driven angiogenesis and identified RhoA/ROCK as the downstream effector pathway for its role in endothelial migration and actin remodeling.

   Evidence siRNA, antibody blockade, tube formation, aortic ring sprouting, collagen gel contraction, and actin/localization immunofluorescence in endothelial cells

   PMID:26350504

   Open questions at the time

   • Direct biochemical link between AAMP and RhoA not yet established at this stage
   • Mechanism of VEGF-dependent recruitment to protrusions unknown
7. 2020 Medium

   Defined a molecular mechanism by which AAMP activates CDC42 — by impairing the ARHGAP1–CDC42 interaction to block GAP-mediated inactivation — explaining protrusion formation in lung cancer cells.

   Evidence Co-immunoprecipitation, CDC42 activation assay, siRNA/overexpression, and migration/invasion assays in NSCLC cells

   PMID:33279622

   Open questions at the time

   • Whether AAMP binds CDC42 and ARHGAP1 simultaneously or competitively not structurally resolved
   • Generality across cell types untested
8. 2021 Medium

   Identified a second GTPase-stabilizing mechanism: AAMP binds RhoA directly and shields it from SMURF2-mediated ubiquitination, increasing active RhoA to drive colorectal cancer invasion.

   Evidence Co-immunoprecipitation, ubiquitination assay, SMURF2 epistasis, knockdown/overexpression, and migration/invasion assays

   PMID:34901393

   Open questions at the time

   • Structural basis for how AAMP blocks SMURF2 access to RhoA unknown
   • Whether AAMP regulates SMURF2 activity broadly not addressed
9. 2022 Medium

   Extended AAMP's interactome to the co-stimulatory protein B7-H3, implicating AAMP in modulation of T-cell responses.

   Evidence Yeast two-hybrid and mass spectrometry screens with BiFC and Co-IP validation, plus 3H-thymidine T-cell proliferation assay

   PMID:35919070

   Open questions at the time

   • Mechanism by which AAMP affects B7-H3 signaling not defined
   • In vivo immune relevance untested
10. 2024 Medium

    Unified AAMP's regulation as a ubiquitination-controlled negative regulator of endothelial barrier function acting on both RhoA and RhoB at actin-rich membrane ruffles.

    Evidence Ubiquitination-inhibitor proteomics (MLN7243/MLN4924), endothelial barrier assays, RhoA/RhoB activity and stability assays, and F-actin/cortactin colocalization in primary endothelial cells

    PMID:39404373

    Open questions at the time

    • E3 ligase controlling AAMP turnover not identified
    • Mechanistic distinction between AAMP control of RhoA versus RhoB unresolved

• How AAMP's distinct activities — Rho/CDC42 GTPase regulation, extracellular heparin/GAG binding, Nod2/NF-κB modulation, and B7-H3-linked immune signaling — are integrated by a single protein, and whether these reflect separable domains or context-dependent functions, remains unresolved.
• No structural model assigning functions to specific domains
• No in vivo or knockout phenotype defining the dominant physiological role
• Crosstalk between cytoskeletal and immune functions unexplored